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ABSTRACT: Nanosized objects, such as nanoparticles and other drug
carriers used in nanomedicine, once in contact with biological environments
are modiﬁed by adsorption of biomolecules on their surface. The presence of
this corona strongly aﬀects the following interactions at cell and organism
levels. It has been shown that corona proteins can be recognized by cell
receptors. However, it is not known whether the composition of this acquired
layer can also aﬀect the mechanisms nanoparticles use to enter cells. This is
of particular importance when considering that the same nanoparticles can
form diﬀerent coronas for instance in vitro when exposed to cells in diﬀerent
serum amounts or in vivo depending on the exposure or administration route.
Thus, in this work, diﬀerent coronas were formed on 50 nm silica by
exposing them to diﬀerent serum concentrations. The uptake eﬃciency in
HeLa cells was compared, and the uptake mechanisms were characterized using transport inhibitors and RNA
interference. The results showed that the nanoparticles were internalized by cells via diﬀerent mechanisms when diﬀerent
coronas were formed, and only for one corona condition was uptake mediated by the LDL receptor. This suggested that
coronas of diﬀerent composition can be recognized diﬀerently by cell receptors, and this in turn leads to internalization
via diﬀerent mechanisms. Similar studies were performed using other cells, including A549 cells and primary HUVEC,
and diﬀerent nanoparticles, namely 100 nm liposomes and 200 nm silica. Overall, the results conﬁrmed that the corona
composition can aﬀect the mechanisms of nanoparticle uptake by cells.
KEYWORDS: biomolecule corona, nanoparticle, uptake mechanisms, transport inhibitors, silica
Nanosized materials are widely investigated for theirpotential use as drug delivery systems thanks to theirability to distribute in the body and enter cells and
the possibility to engineer them for multiple purposes.1−3
Several nanomedicines are already on the market; however it is
recognized that a better understanding of the mechanisms by
which these objects are processed at organism and cell levels
could contribute to further advance their clinical success.4−6
In recent years, particular interest has been drawn on the
impact of the biological environment in which nanomaterials
are applied on their interactions at the organism and cellular
level. Once in contact with a biological environment, nanosized
objects immediately interact with the surrounding biomole-
cules, which can adsorb on the nanoparticle surface, leading to
the formation of a biomolecular corona.7,8 Some of the
biomolecules in this layer associate with the nanoparticle
surface almost irreversibly, aﬀecting de facto the subsequent
behavior. For instance, it has been shown that the formation of
the corona can aﬀect nanomaterial stability and biodistribu-
tion, macrophage sequestration, immune system activation,
cellular recognition, and nanomaterial ﬁnal fate.9−11 In some
cases, the formation of a biomolecular corona can also aﬀect
the speciﬁcity of targeted drugs, by masking targeting ligands
attached to the nanocarrier.12,13 Polymers such as poly-
(ethylene glycol) (PEG) are usually grafted on the nano-
particle surface to partially reduce protein binding and
subsequent macrophage sequestration.14−16 However, recent
work suggested that the so-called stealth eﬀect is actually
conferred by speciﬁc corona proteins adsorbed on PEGylated
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surfaces.17 At the same time, researchers are also trying to
exploit the biomolecular corona as a targeting strategy to direct
nanoparticles toward speciﬁc cellular routes.18−20
So far, corona formation and its composition have been
widely investigated.21−24 It is known that diﬀerent nanoparticle
properties such as size, charge, and shape can inﬂuence corona
composition, and this can lead to diﬀerent cellular responses to
nanomaterials.8,25,26 The corona composition also varies
depending on the nature of the biological ﬂuids in which
nanoparticles are dispersed, such as fetal bovine serum, human
serum, or plasma,27 and even in the same ﬂuid, when the ratio
between nanoparticle and ﬂuid concentration is changed.28 It
has also been shown that the composition of this layer evolves
over time or for instance during nanoparticle exposure to cells,
because of adsorption of biomolecules secreted by cells in the
medium.21,22,29,30
Importantly, several studies have highlighted that the corona
composition aﬀects nanoparticle−cell association31 and that
corona proteins can engage with speciﬁc cell recep-
tors.10,20,32,33 For instance, it has been shown that the uptake
of silica nanoparticles is mediated by the recognition of corona
proteins by the low density lipoprotein (LDL) receptor.10
However, it is not known yet whether the corona composition
and the initial recognition of corona proteins by speciﬁc cell
receptors also aﬀect the following mechanism cells use to
internalize the nanoparticles.
To this aim, in this work we characterized and compared the
mechanisms of uptake of nanoparticles dispersed in media
containing two very diﬀerent serum concentrations, a high
serum content close to protein concentration in blood
(roughly 60 mg/mL) and a 5 times lower one. Silica
nanoparticles (SiO2 nanoparticles) of 50 nm diameter were
used as a representative model system to form diﬀerent
coronas in the two conditions. It is known that varying serum
amount can lead to formation of diﬀerent coronas.28 Then, the
eﬀect of serum content on the uptake eﬃciency in HeLa cells
was investigated, and common pharmacological inhibitors of
endocytosis were used in order to determine potential
diﬀerences in the mechanisms of uptake in the two conditions.
Next, RNA interference was used to silence the expression of
the LDL receptor, here selected as a ﬁrst illustrative example,
given the previous reports on its involvement in the uptake of
similar silica nanoparticles.10 This allowed us to test its
involvement in the initial recognition of the corona proteins by
cells. Finally, similar experiments were performed on diﬀerent
cells, i.e. A549 cells and primary human umbilical vein
endothelial cells (HUVEC), and with diﬀerent nanoparticles,
including 200 nm silica and 100 nm 1,2-dioleoyl-sn-glycero-3-
phospho-(1′-rac-glycerol) (DOPG)−cholesterol liposomes, in
order to translate the results to other systems. In this way, we
have been able to connect the eﬀect of corona composition on
the initial recognition by speciﬁc cell receptors (here the LDL
receptor) with the following mechanisms cells use to
internalize nanoparticles.
RESULTS AND DISCUSSION
Characterization of the Corona−Nanoparticle Com-
plexes. Silica of 50 nm were selected as a well-characterized
model nanoparticle. Extensive information on their corona
properties and interactions with cells is already avail-
able.21,28,34,35 Furthermore, thanks to their density, simple
centrifugation can be used to separate corona-coated nano-
particles from the unbound serum biomolecules, making
isolation of corona−nanoparticle complexes relatively easy
(see Methods and Supplementary Table S1 for details).
In order to form diﬀerent coronas and study their eﬀect on
cellular uptake mechanisms, the nanoparticles were dispersed
in two very diﬀerent serum amounts, a lower and a roughly 5
times higher serum concentration (12 and 62 mg/mL proteins,
respectively). Instead of standard fetal bovine serum, pooled
human serum was used as a more relevant serum source when
testing uptake mechanisms on human cells. Similarly, as a ﬁrst
step, serum was selected instead of plasma to avoid additional
complications related to the choice of the anticoagulant used
to prepare it.36
Exposure of nanoparticles to diﬀerent amounts of proteins
may also aﬀect particle stability, and this, in turn, could aﬀect
the resulting interactions with cells.37−39 Thus, the nano-
particle dispersions in (MEM) cell media supplemented with
the diﬀerent amounts of serum and the corresponding
corona−nanoparticle complexes (low-serum and high-serum
corona−nanoparticle complexes, LC and HC, respectively)
were characterized by dynamic light scattering (DLS) and
diﬀerential centrifugal sedimentation (DCS) (see Figure 1A,
Supplementary Figure S1, and Supplementary Tables S2 and
S3 for details). In some cases, DLS showed small peaks at
larger sizes, suggesting the presence of micrometer-sized
agglomerates. However, the DCS results on the isolated
corona complexes allowed us to exclude the presence of large
agglomerates and conﬁrmed that fairly homogeneous dis-
persions of isolated corona complexes were obtained, including
small agglomerates (such as dimers, trimers, and similar) in the
case of the complexes formed in lower serum (Figure 1A and
Supplementary Table S2).
Next, SDS-PAGE was used to conﬁrm, thatas previously
reported for similar nanoparticles28the dispersion in diﬀer-
ent serum concentrations led to adsorption of diﬀerent
amounts and types of proteins on the surface of the
nanoparticles (Figure 1B, with arrows indicating for illustration
some examples of diﬀerences in the bands detected).
Mass spectrometry was used to characterize the corona
composition (Figure 1C, Table 1, and full list in the
Supporting Information). About 300 diﬀerent proteins were
identiﬁed in both samples, with the 15 most abundant ones
contributing alone to roughly 36% (HC) and 50% (LC) of the
total proteins recovered. As already observed for similar
studies, although most of the proteins were present in both
coronas, the relative abundance of some of them was very
diﬀerent between the two samples. For instance, while
apolipoprotein B-100 content was comparable in the two
cases, the histidine-rich glycoprotein was particularly enriched
in the corona formed at high serum amount, and vice versa
apolipoprotein A-I content was much higher in the corona
formed in low serum.
Nanoparticle Uptake Eﬃciency in Situ and after
Corona Isolation. As a next step, the cellular uptake
eﬃciency of the silica nanoparticles in the diﬀerent serum
conditions was tested. To this aim, HeLa cells were used as a
standard cell model commonly applied for similar uptake
studies, in both the endocytosis and nanomedicine ﬁelds.40−42
Cells were exposed to the nanoparticles in the presence of low
and high serum content in situ or after isolation of the corona−
nanoparticle complexes and removal of the free proteins in
solution (Figure 2). As already reported in the literature, the
uptake eﬃciency in the presence of a high amount of serum
was much lower than for nanoparticles incubated with a low
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amount of serum.10,12 This can be explainedat least in
partby the presence of a high amount of free serum
biomolecules in solution. Since the corona biomolecules can
mediate the uptake of nanoparticles through recognition by
speciﬁc cellular receptors,8,10,12 it is likely that the free serum
proteins in solution might also compete for the same receptors
and, in this way, reduce the uptake levels of the corona−
nanoparticle complexes. Indeed, the uptake was higher when
the corona−nanoparticle complexes were isolated and the free
proteins in solution were removed. Given the very diﬀerent
uptake eﬃciency, in order to focus solely on the eﬀect of
corona composition on the mechanisms of uptake and exclude
additional eﬀects due to the interference of the free serum
molecules in the process, the following studies were performed
using isolated corona−nanoparticle complexes. However, it is
interesting to note that even after removal of the excess free
Figure 1. Characterization of the corona formed on 50 nm silica
nanoparticles in low and high serum content (LC and HC,
respectively). (A) Diﬀerential centrifugal sedimentation (DCS) of
50 nm silica nanoparticles in PBS and the corona−nanoparticle
complexes formed in low or high amount of serum (LC and HC,
respectively), performed as described in the Methods (see also
Supplementary Table S2). (B) SDS-PAGE gel image of the
proteins recovered from corona−nanoparticle complexes formed
in low (lane 1 and 2) or high (lane 3 and 4) human serum and
isolated after 30 min (lane 2 and 4) or 1 h (lane 1 and 3)
centrifugation. The corona formed on 300 μg/mL silica nano-
particles dispersed in 12 and 62 mg/mL human serum,
respectively, was prepared and isolated as described in the
Methods. The gel shows that diﬀerent bands were present in the
two conditions (arrows indicate some examples). M: molecular
weight ladder. (C) Venn diagram of the total amount of proteins
identiﬁed by mass spectrometry in the corona−nanoparticle
complexes formed in the two conditions.
Table 1. List of the Most Abundant Proteins Identiﬁed in
the Corona Formed on 50 nm Silica Nanoparticles in Low







name protein name LC HC
30778 P02647 APOA1 apolipoprotein A-I 17.9 7.0
59578 P04196 HRG histidine-rich
glycoprotein
5.4 9.5
14747 P35542 SAA4 serum amyloid A-4
protein
4.4 2.7
36154 P02649 APOE apolipoprotein E 3.9 3.2
11175 P02652 APOA2 apolipoprotein A-II 3.2 1.9
515611 P04114 APOB apolipoprotein B-100 2.6 2.2
46737 P01009 A1AT alpha-1-antitrypsin 1.7 1.5
39731 P27169 PON1 serum paraoxonase/
arylesterase 1
1.5 0.9
45399 P06727 APOA4 apolipoprotein A-IV 1.5 1.0
15887 P02766 TTHY transthyretin 1.3 1.5
69367 P02768 ALBU serum albumin 1.3 1.3
43974 O14791 APOL1 apolipoprotein L1 1.3 0.8
11765 P01834 IGKC immunoglobulin
kappa constant
1.2 1.2
13532 P0DJI8 SAA1 serum amyloid A-1
protein
1.2 0.7
10852 P02656 APOC3 apolipoprotein C-III 1.0 0.5
total % top 15
proteins
49.5 35.8
aThe corona formed on 300 μg/mL silica nanoparticles dispersed in
12 and 62 mg/mL human serum (low serum corona, LC, and high
serum corona, HC, respectively) was prepared and isolated as
described in the Methods. Thus, the corona proteins were identiﬁed
by mass spectrometry, and their relative abundance over total (% of
total) was quantiﬁed (see Methods for details). The table shows the
relative abundance of the top 15 proteins identiﬁed in the two
conditions.
Figure 2. Uptake kinetics of 50 nm red silica nanoparticles in the
presence of low and high human serum and the respective
corona−nanoparticle complexes. HeLa cells were exposed to 100
μg/mL nanoparticles in a low or high amount of human serum in
situ (4 and 20 mg/mL, respectively, with excess free proteins left in
solution) or to the corresponding corona−nanoparticle complexes
formed at the same nanoparticle to protein ratio, after removal of
the free proteins in excess (see Methods for details). The results
are the average and standard deviation over three replicates of the
median cell ﬂuorescence intensities obtained by ﬂow cytometry.
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Figure 3. Characterization of the uptake mechanisms of the corona−nanoparticle complexes formed on 50 nm silica in low and high
amounts of serum. Brieﬂy, the corona−nanoparticle complexes formed on 300 μg/mL nanoparticles in MEM supplemented with 12 mg/mL
(low-serum corona, LC, middle panels) or 62 mg/mL (high-serum corona, HC, right panels) of human serum were isolated as described in
the Methods and added to HeLa cells at a ﬁnal nanoparticle concentration of 100 μg/mL in serum-free medium, in the presence or absence
of 100 μM EIPA, 10 μg/mL chlorpromazine (CP), 2.5 mg/mL methyl-β-cyclodextrin (MBCD), 25 μg/mL dynasore (Dyn), 2.5 μg/mL
cytochalasin D (CytoD), or 5 μM nocodazole (NZ). For each inhibitor, the left panels show the corresponding controls of drug eﬃcacy, with
HeLa cells exposed to 2 μg/mL Dil-LDL in serum-free MEM as control for chlorpromazine and dynasore, 250 μg/mL 10 kDa TRITC
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serum the uptake eﬃciency was lower for the complexes
formed at higher serum content. Quantiﬁcation by ﬂuores-
cence of the nanoparticles recovered after corona isolation
conﬁrmed that this was not simply due to loss of nanoparticles
in the isolation procedure (Supplementary Table S1).
Confocal ﬂuorescence imaging conﬁrmed uptake of the
corona−nanoparticle complexes formed in both low and high
serum andas observed for most nanomaterials4,43,44
accumulation in the lysosomes (Supplementary Figure S2).
Uptake Mechanisms of Low- and High-Serum
Corona−Nanoparticle Complexes. In order to characterize
the mechanisms of uptake of the diﬀerent corona−nanoparticle
complexes, common pharmacological inhibitors of endocytosis
were used. These compounds are often used to study transport
into cells, given their fast action and apparent ease of
use.41,42,45−48 However, due to their toxicity and limits
connected to their mechanism of action, stringent controls
are needed in order to verify their eﬃcacy and set up protocols
speciﬁc to the cells and conditions applied. We previously
performed an extensive study on these aspects and carefully
optimized their use on HeLa cells, in order to demonstrate
their eﬃcacy and minimize their toxicity.49 The same
conditions were applied for this study. There, we also found
that the presence of serum can strongly limit the eﬃcacy of
some of these compounds. Thus, by using isolated corona
complexes in serum-free conditions, we ensured optimal
eﬃcacy of all the inhibitors. Moreover, we performed time-
resolved uptake studies in order to follow the kinetics of the
process. Time-resolved studies allowed us to rule out the
contribution of potential nanoparticles adhering outside cells,
which can confuse uptake results at a single exposure time,
especially when short.50
A panel of six diﬀerent inhibitors was used. Figure 3 shows
one representative example of the kinetics of uptake of
corona−nanoparticle complexes formed in low and high
amounts of serum (central and right panels) in the presence
or absence of each of the diﬀerent inhibitors. In every
experiment and for each compound, a control to conﬁrm
inhibitor eﬃcacy was also included (Figure 3, left panels).
These results, together with two other independent replicates,
are shown in Supplementary Figure S3 after normalization for
the uptake in cells without inhibitors. Their normalized average
Figure 3. continued
dextran in complete MEM as control for EIPA, and 1 μM LacCer in serum-free MEM for methyl-β-cyclodextrin. Uptake kinetics were
obtained by ﬂow cytometry, and the results are the average and standard deviation over three replicates of the median cell ﬂuorescence
intensities of cells exposed to control markers or corona complexes with or without the diﬀerent inhibitors. Immunostaining of actin and
tubulin was used to conﬁrm eﬃcacy of cytochalasin D and nocodazole, respectively (see Methods for details). In the confocal ﬂuorescence
images: blue DAPI-stained nuclei and red-stained actin or tubulin. Scale bar: 100 μm.
Figure 4. Overview of the eﬀects of transport inhibitors on the uptake of the corona−nanoparticle complexes formed on 50 nm silica in low
and high amounts of serum. Brieﬂy, the corona complexes formed on 300 μg/mL nanoparticles in MEM supplemented with 12 mg/mL (low-
serum corona) or 62 mg/mL (high-serum corona) of human serum were isolated as described in the Methods and incubated on HeLa cells
at a ﬁnal nanoparticle concentration of 100 μg/mL in serum-free medium, in the presence or absence of 100 μM EIPA, 10 μg/mL
chlorpromazine, 2.5 mg/mL methyl-β-cyclodextrin (MβCD), 25 μg/mL dynasore, 2.5 μg/mL cytochalasin D, or 5 μM nocodazole. Data are
normalized for the uptake in cells without inhibitors to show the inhibition eﬃcacy. The results are the average and standard error of the
median cell ﬂuorescence intensities obtained in three independent experiments (with the exception of the last exposure time, 6 h, for cells
exposed to nocodazole, and the last exposure time, 7 h, for cells exposed to for chlorpromazine in low-serum corona, which were performed
once). The results of the individual experiments are shown in Supplementary Figure S3. A black dashed line and a red dashed line are
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is shown in Figure 4 as an overview of the inhibition eﬃcacy
(see Methods for details).
Chlorpromazine hydrochloride was used as a commonly
used inhibitor of clathrin-mediated endocytosis,41,46,47 one of
the most relevant and characterized mechanisms of cellular
uptake. It is generally believed that nanoparticles and drug
carriers with sizes up to roughly 100 nm typically use clathrin-
mediated endocytosis to enter cells.41,51 Cells exposed to
chlorpromazine showed up to 70% reduction of uptake of 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate
(Dil)-labeled LDL, known to enter cells via this mechanism,52
conﬁrming drug eﬃcacy in the conditions applied. Interest-
ingly, while for the complexes formed at low serum content
uptake was substantially reduced in the presence of
chlorpromazine (up to 75% reduction at the latest exposure
time), only minor eﬀects could be observed for the complexes
formed at high serum content, with an uptake reduction
between 0 and maximum 30% at diﬀerent exposure times in
diﬀerent replicate experiments (Figures 3 and 4 and
Supplementary Figure S3). This suggests that clathrin-
mediated endocytosis is involved in the uptake of these
nanoparticles only when they are added to cells in the presence
of lower amounts of serum.
Next, EIPA (5-(N-ethyl-N-isopropyl)amiloride) was used as
inhibitor of macropinocytosis.53,54 This mechanism involves an
actin-driven formation of membrane ruﬄes to engulf a portion
of extracellular medium.55 Several examples in the literature
have suggested the involvement of this mechanism in the
uptake of nanomedicines and nanoparticles.48,56 EIPA eﬃcacy
on HeLa cells was conﬁrmed using a ﬂuorescent ﬂuid phase
marker, 10 kDa TRITC dextran; its uptake was reduced up to
80% after 5 h in the presence of EIPA. For the corona−
nanoparticle complexes formed at low serum content, the
uptake in the presence of EIPA was reduced from 50% to 80%
at increasing exposure times, but for the complexes formed at
high serum content only minor eﬀects were observed (in the
averaged results of Figure 4, between 0 and maximum 30%
reduction at increasing exposure times). These results suggest
that macropinocytosis is involved in the uptake of corona−
nanoparticle complexes formed in the presence of a low
amount of serum, with only minor eﬀects at high-serum
content.
The role of cholesterol in the uptake mechanism was
assessed by using methyl-β-cyclodextrin, a compound that
sequesters the cholesterol in the cell membrane, often used as
an inhibitor of lipid-raft-mediated mechanisms. Methyl-β-
cyclodextrin eﬃcacy on HeLa cells was conﬁrmed by
measuring the uptake of a ﬂuorescent sphingolipid, BODIPY
FL C5-lactosylceramide/BSA complex (LacCer).46,57 The
results showed 70% reduction in LacCer uptake in the
Figure 5. Involvement of the LDL receptor (LDLR) in the uptake of the corona−nanoparticle complexes formed on 50 nm silica in low and
high amounts of serum. Brieﬂy, the expression of the LDL receptor was silenced as described in the Methods (siLDLR). Cells silenced with a
scramble siRNA were used as control (Neg siRNA). Then, the corona−nanoparticle complexes formed on 300 μg/mL nanoparticles in MEM
supplemented with 12 mg/mL (LC, low-serum corona) or 62 mg/mL (HC, high-serum corona) of human serum were isolated as described
in the Methods and incubated on HeLa cells at a ﬁnal nanoparticle concentration of 100 μg/mL in serum-free medium for 14 h. The uptake
of 1 μg/mL Dil-labeled LDL after 4.5 h exposure was measured to conﬁrm silencing eﬃcacy. (A) Uptake of LDL and HC or LC complexes
on cells silenced for the LDL receptor, normalized by the uptake in control cells silenced with a scrambled siRNA. The results are the
average and standard error of the median cell ﬂuorescence intensity obtained by ﬂow cytometry in three independent experiments. A black
dashed line is included as a reference at 100% uptake. (B−D) Raw results (without normalization) of one representative experiment for the
uptake of LDL (B), high-serum corona (C), and low-serum corona (D). The ﬂuorescence of untreated control cells is included as a reference
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presence of methyl-β-cyclodextrin. Also in this case, nano-
particle uptake was strongly reduced for corona formed at low
serum content (from 40% to 70% at increasing exposure
times), whereas no eﬀect was observed for the complexes
formed at high serum content.
Next, dynasore was used to inhibit dynamin, a key protein
for several pathways of endocytosis, including clathrin-
mediated endocytosis and other dynamin-dependent mecha-
nisms.58,59 Dynamin mediates the scission of the cell
membrane for the formation of the endosome. Dynasore
eﬃcacy on HeLa cells was conﬁrmed by the strong reduction
(75%) on the uptake of LDL in its presence. In cells exposed
to dynasore, the uptake of the LC and HC complexes was
reduced up to 30% in the ﬁrst 5 h of exposure, while the
inhibition seemed to increase to 60% and 40%, respectively, at
the longest exposure time.
Finally, the role of the actin cytoskeleton and microtubules
was studied using respectively cytochalasin D and nocoda-
zole.60,61 Actin has a predominant role for macropinocytosis to
mediate the formation of membrane ruﬄes.55 However, it is
involved also in several other mechanisms, including clathrin-
mediated endocytosis.62,63 Disruption of actin and micro-
tubules upon treatment with the inhibitors was conﬁrmed by
confocal microscopy using TRITC-phalloidin or an antibody
against α-tubulin (Figures 3). For the LC complexes, only
minor uptake reduction could be observed in the presence of
cytochalasin D (on average a maximum 30% reduction). On
the other hand, nocodazole had a strong eﬀect on the uptake of
these complexes (40−50% reduction at all exposure times).
For the complexes formed in high serum instead, both
cytochalasin D and nocodazole showed a similar trend, with
the uptake reduction increasing up to 40% over time, possibly
suggesting an actin and microtubule-driven mechanism at the
longer exposure times.
Overall, the results suggest an involvement of multiple
mechanisms in the two conditions. In the case of the corona−
nanoparticle complexes formed in low amount of serum (white
bars in Figure 4), clathrin-mediated endocytosis and macro-
pinocytosis seem involved in the uptake, which also depends
on cholesterol and microtubules. The limited eﬀects observed
with cytochalasin D, however, seem in contrast with the
observed involvement of macropinocytosis. The time-resolved
study also suggests a role for dynamin, mainly at longer
exposure times.
Figure 6. Characterization of the uptake mechanisms of the corona−nanoparticle complexes formed on 50 nm silica in low and high
amounts of serum in A549 (A and B) and HUVEC (C and D) cells. Brieﬂy, the corona−nanoparticle complexes formed on 300 μg/mL 50
nm silica nanoparticles in MEM supplemented with 12 mg/mL (LC, low serum corona) or 62 mg/mL (HC, high serum corona) of human
serum were isolated as described in the Methods and incubated on cells at a ﬁnal nanoparticle concentration of 100 μg/mL in serum-free
medium. A549 (A) and HUVEC (C) cells were exposed for 6 h to the nanoparticles in the presence of chlorpromazine (CP), EIPA, methyl-
β-cyclodextrin (MBCD), dynasore (Dyn), cytochalasin D (CytD), or nocodazole (NZ) (see Methods for details of concentrations for each
cell line). Data are normalized for the uptake in cells without inhibitors. The results are the average and standard error of the median
ﬂuorescence intensity obtained in two independent experiments, which are shown in Supplementary Figure S5. A black dashed line and a red
dashed line are included as a reference, at 100% and 60% uptake, respectively (with 60% uptake shown as an indicative threshold for
inhibition eﬃcacy). (B) Uptake of LC or HC corona−nanoparticle complexes (14 h exposure) and 1 μg/mL Dil-labeled LDL (4.5 h
exposure) in A549 cells silenced for the LDL receptor (as described in the Methods). The results are the average and standard error of the
median ﬂuorescence intensity obtained in three independent experiments, normalized by the uptake in control cells silenced with a
scrambled negative siRNA. (D) Uptake of LC or HC nanoparticle complexes by HUVEC in the presence of increasing amounts of unlabeled
LDL (12× = 36 μg/mL; 24× = 73 μg/mL; 50× = 146 μg/mL, with respect to the number of nanoparticles added) or with bovine serum
albumin (BSA 50× = 4,2 μg/mL) (14 h exposure). The results are the average and standard deviation over three replicates of the median cell
ﬂuorescence intensity obtained by ﬂow cytometry, normalized by the uptake in cells exposed to the corona complexes in serum-free medium
with the same volume of PBS added (PBS).
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Instead, in the case of corona−nanoparticle complexes
formed in high amount of serum (gray bars in Figure 4) several
diﬀerences were observed, and overall all inhibitors seemed to
have minor eﬀects in reducing nanoparticle uptake, perhaps
increasing at the longer exposure times. One reason for this
can be connected to the slower uptake kinetics for these
complexes, even after corona isolation, making it harder to see
clear eﬀects on uptake when inhibitors are added (Figure 3,
right panels). Unfortunately, these compounds cannot be used
for much longer time, due to their intrinsic toxicity.4,46
Nevertheless, the results suggested that, especially at the
longest exposure times, HC uptake is partially dependent on
dynamin, actin, and microtubules, however with eﬀects never
stronger than a 40% uptake reduction. On the other hand, as
opposed to what was observed for LC complexes, clearly
clathrin-mediated endocytosis, macropinocytosis, and choles-
terol did not appear to be involved in the uptake of these
nanoparticles when corona was formed at high serum content.
As a next step, we investigated the potential mechanisms
beyond the observed diﬀerences. We hypothesized that
diﬀerent coronas are recognized diﬀerently by cell receptors,
and this may lead to activation of diﬀerent uptake mechanisms.
To test this hypothesis, we used RNA interference to
selectively shut down the expression of the LDL receptor
and test its involvement in the recognition of the corona
complexes in the two conditions (Figure 5). It was previously
shown that in A549 lung epithelial cells the uptake of 100 nm
silica nanoparticles dispersed in human serum was mediated by
the recognition of the apolipoprotein B-100 present in the
corona by the LDL receptor.10 For each experiment, silencing
eﬃcacy was conﬁrmed by measuring the uptake of labeled
LDL. The results conﬁrmed that silencing the expression of the
LDL receptor reduced LDL uptake by about 60% (Figure 5A
and B). Interestingly, even in HeLa cells and with the smaller
50 nm silica nanoparticles used for this study, silencing the
expression of the LDL receptor reduced the uptake of the
corona complexes formed in higher serum amount (Figure 5A
and C), conﬁrming its involvement in the uptake of these
nanoparticles also in HeLa cells. However, no reduction
(rather a strong increase) was observed in the uptake of the
Figure 7. Characterization of the uptake mechanisms of the corona−nanoparticle complexes formed on 200 nm silica (A−C) and 100 nm
liposomes (D−F) in low and high amount of serum in HeLa cells and corona composition. Brieﬂy, the corona−nanoparticle complexes
formed on 1200 μg/mL 200 nm silica nanoparticles or 300 μg/mL liposomes in MEM supplemented with 12 or 62 mg/mL human serum
(low and high corona complexes, respectively, LC and HC complexes) were isolated as described in the Methods and incubated on cells in
serum-free medium at a ﬁnal nanoparticle concentration of 300 or 50 μg/mL, respectively. (A and D) Uptake in HeLa cells in the presence
of chlorpromazine (CP), EIPA, methyl-β-cyclodextrin (MBCD), dynasore (Dyn), cytochalasin D (CytD), or nocodazole (NZ) (see Methods
for details) after 7 h (A) or 5 h (D) exposure. Data are normalized for the uptake in cells without inhibitors. The results are the average and
standard error of the median ﬂuorescence intensity obtained in two independent experiments, which are shown in Supplementary Figure S7.
A black dashed line and a red dashed line are included as a reference, at 100% and 60% uptake, respectively (with 60% uptake shown as an
indicative threshold for inhibition eﬃcacy). (B and E) Uptake of HC or LC complexes (14 h exposure) and 1 μg/mL Dil-labeled LDL (4.5 h
exposure) in HeLa cells silenced for the LDL receptor (as described in the Methods). The results are the average and standard error of the
median ﬂuorescence intensity obtained in three independent experiments, normalized by the uptake in control cells silenced with a
scrambled negative siRNA. (C and F) SDS-PAGE gel image of the proteins recovered on corona−nanoparticle complexes formed in low
(LC) or high (HC) human serum content. The corona was prepared and isolated as described in the Methods. The gel images show that
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corona complexes formed in low serum (Figure 5A and D).
This suggests that, in agreement with our hypothesis, the
diﬀerent coronas formed on the 50 nm silica are recognized
diﬀerently by the LDL receptor, and this, in turns, leads to the
activation of diﬀerent pathways for their internalization, as we
observed (Figures 3 and 4).
It is interesting to notice that, in our system, the mass
spectrometry results showed that apolipoprotein B-100, the
major ligand of this receptor, was present in both coronas and
in comparable amounts (Table 1). This indicates that the
presence of certain proteins in the corona, alone, does not
necessarily imply recognition by the corresponding cell
receptors for nanoparticle internalization. Similarly, it is also
most likely that other receptors, not investigated here, are
involved in the two cases.
Next, we tested our hypothesis on other common cell
models, namely, human lung epithelial cancer cells (A549) and
primary HUVEC. Also for these cells, the conditions for using
the panel of inhibitors were optimized in order to exclude
toxicity and conﬁrm drug eﬃcacy (Supplementary Figures S4
and S5). Since diﬀerent cell types express diﬀerent cell
receptors on the plasma membrane and uptake mechanisms
are also diﬀerently active, we expected some diﬀerences in the
way 50 nm silica nanoparticles were internalized by these cells.
Indeed, the results showed that the eﬀects of the inhibitors on
the uptake of the HC and LC complexes were diﬀerent in
A549 cells and HUVEC (Figure 6) and with respect to what is
observed in HeLa cells (Figure 4). In A549 cells overall the
eﬀects of the inhibitors on nanoparticle uptake were minor,
with the exception of dynasore, which suggested a clear role for
dynamin in the mechanisms involved in the uptake of both HC
and LC complexes (Figure 6A and Supplementary Figure S5
for experiment replicates). In HUVEC most of the inhibitors
reduced the uptake of nanoparticles, but no major diﬀerences
between the two corona conditions were observed (Figure 6C
and Supplementary Figure S5). These results suggest that in
A549 cells and HUVEC similar mechanisms are involved in the
uptake of the corona complexes formed in low and high
amounts of serum. We then tested the involvement of the LDL
receptor in all conditions. Interestingly, in A549 cells, as
opposed to what was observed in HeLa cells, silencing the
expression of the LDL receptor led to a strong reduction in the
uptake of both the HC and LC complexes (Figure 6B). For the
HUVEC, given the poor silencing eﬃcacy in primary cells,
LDL was added to the cells together with the corona−
nanoparticle complexes in order to assess potential competi-
tion for the LDL receptor (Figure 6D). Although not as
speciﬁc as silencing, adding increasing concentrations of
unlabeled LDL caused a progressive reduction of the uptake
of both the HC and LC complexes (the same was not observed
when bovine serum albumin (BSA) was added, as a control),
suggesting that the LDL receptor is involved in their
internalization, possibly together with other LDL receptors,
for which LDL could also compete.
Understanding all the factors controlling corona recognition
by cell receptors and how these change in diﬀerent cells
remains a central challenge for the ﬁeld, far beyond the scope
of this paper. Nevertheless, these results suggest that when the
same receptor is engaged (in this particular example, the LDL
receptor), the same mechanisms are involved in the following
internalization. This conﬁrms the hypothesis that the initial
recognition of corona proteins by speciﬁc cell receptors can
aﬀect the mechanisms of internalization.
As a ﬁnal step, we performed similar experiments using other
nanoparticles of diﬀerent sizes and materials. For this purpose,
we selected larger silica nanoparticles of 200 nm in diameter
and 100 nm DOPG−cholesterol liposomes, as an example
closer to the materials used in nanomedicine. Also with these
nanoparticles, diﬀerent coronas were formed by incubation
with two diﬀerent amounts of serum, followed by isolation of
the corona−nanoparticle complexes by centrifugation andin
the case of the liposomessize exclusion chromatography (see
Methods for details). DLS characterization showed that for
both materials good dispersions of the isolated corona−
nanoparticles complexes could be obtained in both serum
conditions (Supplementary Table S3 and Supplementary
Figure S6). For the 200 nm silica, this was further conﬁrmed
by DCS and nanoparticle tracking analysis (NTA) (also in
Supplementary Figure S6). SDS-PAGE showed that with both
nanoparticles dispersion in diﬀerent serum concentrations led
to the adsorption of diﬀerent proteins on their surface (Figure
7C and F, with arrows to show some examples of bands with
diﬀerent intensities in the two conditions).
Then, the panel of transport inhibitors was used to
characterize the mechanisms of uptake in HeLa cells. The
results showed that, as expected, diﬀerent mechanisms were
involved in the uptake of 200 nm silica and of the liposomes
(Figure 7A and D, respectively, and Supplementary Figure S7
for experiment replicates), with respect to what was observed
for the 50 nm silica (Figure 4).
Interestingly, as observed for the 50 nm silica, also for the
200 nm silica diﬀerent mechanisms were involved in the
uptake of corona−nanoparticle complexes formed in low and
high serum amounts, the latter involving dynamin and
microtubules (Figure 7A). This is a further conﬁrmation that
the corona composition can aﬀect the mechanisms cells use to
internalize nanoparticles.
In the case of the liposomes, instead, for most inhibitors no
major diﬀerences were found in the two conditions. However,
cholesterol depletion reduced the uptake of HC complexes by
60%, with only minor eﬀects for LC ones (Figure 7D),
conﬁrming once more eﬀects of corona composition on the
uptake mechanisms.
As a ﬁnal test, we assessed the involvement of the LDL
receptor in the uptake of these nanoparticles. The results
showed that for both nanoparticles and the diﬀerent corona
complexes silencing the expression of the LDL receptor did
not aﬀect uptake (Figure 7B and E). This indicates that in the
case of these two nanoparticles other receptors are involved in
the uptake. Further studies are required to identify all receptors
involved in each case, including for the 50 nm silica, for which
additional ones are likely to be involved, together with the
LDL receptor.
In conclusion, the results presented indicate that the same
nanoparticles can enter cells via diﬀerent mechanisms when
coated by coronas of diﬀerent composition following
dispersion in diﬀerent protein contents. Changing protein
concentration can also aﬀect nanoparticle stability and, as a
consequence of that, the following interactions with cells.37−39
Indeed, in the case of the 50 nm silica, the presence of small
agglomerates observed by DCS at lower serum content (Figure
1A) may contribute in part to some of the diﬀerences observed
on HeLa cells in the uptake mechanisms of the LC and HC
complexes (Figure 4). However, diﬀerences in uptake
mechanisms were observed also with liposomes and 200 nm
silica (Figure 7), for which characterization clearly showed that
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homogeneous dispersions of isolated corona−nanoparticle
complexes were obtained (Supplementary Figure S6). This
excludes that the observed diﬀerences in uptake mechanisms
are solely due to diﬀerences in nanoparticle stability and
further conﬁrms the hypothesis that corona composition can
aﬀect the mechanisms cells use to internalize nanoparticles.
CONCLUSIONS
So far, most studies on the mechanisms nanoparticles use to
enter cells have adopted either serum-free conditions or
dispersion in standard cell culture medium supplemented with
a low amount of (bovine) serum. Serum is added to cell
cultures simply for providing nutrients to cells. However, the
presence of biological ﬂuids has much more profound eﬀects
on the interactions of nanosized objects with cells, due to the
adsorption of molecules on their surface and corona
formation.7 Cell receptors can recognize and engage with
such corona proteins, and overall it is known that this layer
strongly aﬀects the subsequent interactions with cells.10
Given that corona proteins can be recognized by speciﬁc cell
receptors, it comes natural to wonder whether this layer can
also aﬀect the mechanisms cells use to internalize nanosized
objects. Recent works have shown that the presence or absence
of a corona has an impact on the mechanisms cells use to
internalize nanosized materials.64,65 However, it is not known
whether the corona composition (as opposed to simply the
presence of a corona) also matters. This is of particular
importance given that the same nanoparticles can form very
diﬀerent coronas depending on the biological ﬂuid in which
they are applied (thus the exposure route or, for nano-
medicines, the administration route) and also on its
concentration.7,66 The implications can be profound. For
instance, in vivo, nanoparticles in blood encounter much higher
serum concentrations than what is usually applied in in vitro
studies (passivating nanomedicines by exposure to serum prior
to their administration in vivo may be considered in the future
as an approach to try to control uncertainties related to
changes in corona composition). Indeed, our results suggest
that the corona composition can aﬀect the initial recognition
by cell receptors and, as a result, the same nanoparticle can be
internalized by cells using diﬀerent mechanisms when diﬀerent
coronas are formed. Potential subtle diﬀerences in nanoparticle
stability for diﬀerent coronas could also contribute in part to
similar diﬀerences and should also be considered.
Another interesting observation is that nanoparticle uptake
is lower at higher serum content. Similar observations were
already reported for experiments where the excess proteins
were left in situ,12,67 possibly due to competition with the
corona proteins for the same receptors.10 However, here lower
uptake was observed also after corona isolation and removal of
excess free proteins. The lower uptake could be related to
speciﬁc diﬀerences in corona composition. For instance, a
study on macrophages suggested that the presence of histidine-
rich glycoprotein in the corona is associated with a decreased
uptake.68 Here, similarly, the observed higher abundance of
this protein in the corona formed at higher serum content
could be one of the factors contributing to their lower uptake.
Further studies are necessary to fully demonstrate similar
eﬀects connected to the relative abundance of individual
proteins in the corona.
Next to this, the results suggest that multiple uptake
mechanisms seem involved at the same time in the uptake of
nanoparticles. It has been previously hypothesized that, within
a sample, multiple subpopulations of diﬀerent coronas may be
formed,7 and this could explainat least in partthe
observed co-presence of diﬀerent uptake mechanisms. More
subtle changes of corona composition over time and during
exposure to cells could also explain this observation. Further
studies are required to fully characterize the molecular details
of the mechanisms involved in each case, possibly combining
the use of transport inhibitors and RNA interference with
other methods, such as the use of genetically modiﬁed cells.
Overall, these results clearly highlight the importance of
deﬁning what the “correct corona” is for each nanomedicine
(or nanoparticle) when investigating its behavior on cells. For
instance, for nanomedicines administered by injection, not
only higher serum content but also other factors likely to aﬀect
corona composition should be considered, such as the
presence of blood ﬂow and the more complex composition
of plasma in vivo (as opposed to the serum used here).13,36
Similar considerations should also be applied to nano-
medicines administered via diﬀerent routes, for instance
inhaled or ingested nanomedicines, for which a serum corona
may be not relevant. Additionally, other more complex factors
such as the evolution of corona composition over time and
changes due to the interaction with secreted cellular
biomolecules may also aﬀect the uptake mechanisms on
cells.21,22,29,30
Finally, while we could partially resolve the role of a
particular receptor, here the LDL receptor, in mediating
nanoparticle uptake in the diﬀerent conditions tested, it is
likely that many other receptors are involved, depending on the
cell type, the nanoparticle, and the corona. Much more work
will be required in this ﬁeld to fully disentangle which epitopes
are exposed on the outer surface of the corona and may be
accessible for recognition by cells. Some ﬁrst works have
started to address this aspect and have illustrated its
complexity.17,69 Nevertheless, the phenomenon reported has
profound implications for the ﬁeld, and it is rather surprising to
discover that this acquired layer can have such deep
implications in the way cells process nanomaterials.
METHODS
Cell Culture. HeLa cells (ATCC CCL-2) and adenocarcinomic
human alveolar basal epithelial cells (A549) (ATCC CCL-185) were
cultured at 37 °C, 5% CO2 in complete cell culture medium (cMEM)
consisting of MEM (Gibco ThermoFisher Scientiﬁc) supplemented
with 10% v/v fetal bovine serum (FBS, Gibco ThermoFisher
Scientiﬁc). All experiments were performed with cells cultured for
no longer than 20 passages after defrosting. Cells were tested monthly
to exclude mycoplasma infection. HUVEC from pooled donors
(LONZA) were cultured at 37 °C, 5% CO2 in endothelial cell growth
medium (Endothelial Cell Growth Medium 2, Promocell). In order to
limit cell senescence and loss of the primary cell characteristics,
experiments were performed using HUVEC from passage 2 to
maximum 7. The medium was refreshed every 48 h.
Nanoparticle Characterization by DLS. Fluorescently labeled
50 and 200 nm silica nanoparticles (SiO2) were purchased from
Kisker Biotech. Nanoparticles were labeled by the manufacturer
during polymerization using a ﬂuorescent monomer with excitation
and emission of 569/585 nm, respectively. Liposomes labeled with Dil
dye with excitation and emission of 549/565 nm, respectively, were
prepared as described below. Nanoparticle stability was assessed by
measuring the particle hydrodynamic diameter by DLS using a
Malvern Zetasizer Nano ZS (Malvern Instruments Ltd.) using
disposable capillary cells (Malvern). The same instrument was used
to measure nanoparticle zeta potential. Brieﬂy, 100 μg/mL 50 and 200
nm silica and 300 μg/mL liposomes were dispersed in 1 mL of dH2O
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or PBS. Silica nanoparticles of 50 nm were also dispersed in MEM
supplemented with 4 or 20 mg/mL pooled human serum (TCS
BioSciences Ltd.). Additionally, the nanoparticle−corona complexes
of 50 and 200 nm silica and of liposomes formed as described below
were also characterized after isolation and dispersion in serum-free
MEM at the same ﬁnal concentration as applied on cells. In all cases,
for each sample, at least three measurements of ﬁve runs each were
performed.
Diﬀerential Centrifugal Sedimentation. Diﬀerential centrifugal
sedimentation was performed using a CPS disc centrifuge model
DC24000 (CPS Instruments Inc.) with an 8−24% sucrose gradient
using water as the aqueous component (Merck) and a rotation speed
of 18 000 rpm. Each particle size measurement was calibrated using
100 μL of a PVC standard with a nominal diameter of 0.237 μm (CPS
Instruments Inc.). A 200 μL amount of 1 mg/mL silica nanoparticle
dispersions in PBS or of the corona complexes formed as described
below was injected. Two (200 nm silica) to three (50 nm silica)
independent repetitions from separate corona−nanoparticle complex
preparations were performed.
Nanoparticle Tracking Analysis. The corona complexes formed
on 200 nm silica nanoparticle were characterized by nanoparticle
tracking analysis using a ZetaView TWIN instrument (Particle
Metrix). All samples were diluted in PBS to a ﬁnal volume of 1
mL. Optimal measurement concentrations were found by pretesting
the particle per frame value (100−200 particles/frame) and were
typically a dilution of 1:10 000 from 1 mg/mL corona complexes or
nanoparticles in PBS. For each sample, three technical replicates of
one cycle were performed by scanning 11 cell positions each and
capturing 60 frames per position (video setting: medium) under the
following settings: focus, autofocus; camera sensitivity, 75.0; shutter,
100; scattering intensity, between 4 and 7; cell temperature, 25 °C.
After capture, the videos were analyzed by the built-in ZetaView
Software 8.05.05 with speciﬁc analysis parameters, which are a
maximum particle size of 1000, a minimum particle size of 5, and a
minimum particle brightness of 50. Two independent measurements
on separate corona−nanoparticle complex preparations were
performed.
Liposome Preparation and Characterization. Liposomes were
prepared by thin lipid ﬁlm hydration, followed by freeze−thaw cycles
and extrusion. Brieﬂy, DOPG, cholesterol (Avanti Polar Lipids), and
the lipophilic dye Dil (Sigma-Aldrich) in a molar ratio of 2.5:1:0.005
were dissolved and mixed in chloroform. The organic solvent was
evaporated with dry nitrogen for 30 min and under vacuum overnight.
Then, the lipid ﬁlm was hydrated with PBS to produce large
multilamellar liposomes at a ﬁnal concentration of 10 mg/mL lipids.
Small unilamellar liposomes were obtained by eight freeze and thaw
cycles in liquid nitrogen and warm water and 21 extrusions through a
0.1 μm polycarbonate membrane using the Avanti mini-extruder
(Avanti Polar Lipids). Zeta spin desalting columns (7K MWCO, from
ThermoFisher Scientiﬁc) were used to remove potential free Dil.
Liposomes were stored at 4 °C and used for a maximum of one
month after preparation. The ﬁnal lipid concentration was quantiﬁed
via Stewart assay.70 For this, a ferrothiocyanate reagent was prepared
ﬁrst by dissolving 27 mg of ferric chloride hexahydrate (Sigma-
Aldrich) and 30.4 mg of ammonium thiocyanate (Sigma-Aldrich) in 1
mL of Milli-Q water. Then, 10 μL of liposomes was mixed with 1 mL
of chloroform and 1 mL of ferrothiocyanate reagent, followed by 1
min vortex and 10 min centrifugation at 300g. The organic phase was
transferred to a quartz cuvette, and the absorbance was measured at
470 nm with a Unicam UV500 spectrophotometer (Unicam
Instruments). The lipid concentration was calculated according to a
standard curve.
Silica Corona−Nanoparticle Complex Preparation and
Characterization. Corona−nanoparticle complexes were formed
and isolated before incubation on cells and characterization. Brieﬂy,
300 μg/mL 50 nm or 1200 μg/mL 200 nm silica nanoparticles were
dispersed in MEM containing roughly 62 mg/mL (HC nanoparticles)
or 12 mg/mL (LC nanoparticles) pooled human serum (TCS
BioSciences) diluted in PBS at 37 °C under continuous shaking (250
rpm). After 1 h of incubation the dispersion was centrifuged for 1 h at
15 °C (for 50 nm silica) or 30 min (for 200 nm silica) at 16000g in
order to pellet the corona−nanoparticle complexes. The supernatant
containing unbound serum was collected, and its ﬂuorescence at 600
nm after excitation at 550 nm measured with a SpectraMax Gemini
XPS microplate spectroﬂuorometer (Molecular Devices), together
with that of the resuspended pellet in order to verify that no
nanoparticles were left in solution and all of them were recovered in
the pellet (see Supplementary Table S1 for details). The pellet
containing corona−nanoparticle complexes was resuspended to 1 mg/
mL nanoparticle in PBS by careful pipeting. For cell experiments with
isolated corona−nanoparticle complexes, for 50 nm silica nano-
particles the complexes were further diluted in serum-free MEM to a
ﬁnal concentration of 100 μg/mL and then added to cells. For 200
nm silica, the corona−nanoparticle complexes were diluted in serum-
free MEM to a ﬁnal concentration of 300 μg/mL for 7 h of exposure
on cells for uptake studies with the inhibitors and 25 μg/mL for 14 h
of exposure for silencing experiments. For SDS PAGE and mass
spectrometry analysis, instead, the corona−nanoparticle complexes
were washed in 1 mL of PBS and centrifuged again at 16000g for 1 h
for 50 nm silica (or 30 min, for 200 nm silica) for a total of four
centrifugations, in order to isolate hard corona-coated nanoparticles.
The ﬁnal amount of nanoparticles present in the pellet after four
washing steps was quantiﬁed again as above with a spectroﬂuor-
ometer. Afterward, the corona−nanoparticle complexes were
resuspended in gel loading buﬀer, boiled 5 min at 95 °C, and loaded
into a 10% polyacrylamide gel for SDS-PAGE. The complexes
recovered were quantiﬁed by ﬂuorescence measurement as described
above, and the same amount of high and low corona−nanoparticle
complexes were loaded in each well. After the electrophoretic run, the
gel was incubated for 1 h with a solution containing 0.1% w/v
Coomassie blue R-250 in a water/methanol/glacial acetic acid (5:4:1)
solution and washed with Milli-Q water, and pictures were taken
using a ChemiDoc XRS (Biorad).
For the isolation of the corona−nanoparticle complexes for
diﬀerential centrifugal sedimentation and nanoparticle tracking
analysis, the samples (prepared as described above) were spun
down using a benchtop Eppendorf centrifuge (Sigma 3-30KS) for 40
min at 4 °C at 14000g (50 nm silica) or 15 min at 16000g (200 nm
silica).
Corona−Liposome Complex Preparation and Character-
ization. Liposomes (300 μg/mL) were incubated with 12 or 62 mg/
mL human serum at 37 °C, 250 rpm. After 1 h of incubation, size
exclusion chromatography was used to separate the liposome−corona
complexes from the unbound proteins. Brieﬂy, 1 mL of sample was
loaded on a 15 × 1.5 cm Sepharose CL-4B column (Sigma-Aldrich)
equilibrated with PBS. The eluate was collected in fractions of 0.5 mL.
The absorbance of each fraction was measured at 280 nm (for
proteins) and 549 nm (for Dil) using a NanoDrop One Microvolume
UV−vis spectrophotometer (ThermoFisher Scientiﬁc). The fractions
containing the liposome−corona complexes were pooled together and
concentrated by using an Amicon Ultra-15 centrifugal ﬁlter (30 kDa,
Millipore) for 1 h at 1700g. The lipid concentration was measured by
a Stewart assay, as described above, and the liposome−corona
complexes were dispersed in serum-free MEM and incubated on cells
at a ﬁnal concentration of 50 μg/mL for 5 h for uptake studies with
the inhibitors and for 14 h for silencing experiments. For SDS PAGE,
the corona−liposome complexes were further concentrated and then
resuspended in gel loading buﬀer, boiled 5 min at 95 °C, and loaded
into a 10% polyacrylamide gel for SDS-PAGE. After the electro-
phoretic run, the gel was incubated for 1 h with a solution containing
0.1% w/v Coomassie blue R-250 (Sigma-Aldrich) in a water/
methanol/glacial acetic acid (5:4:1) solution and washed with Milli-Q
water, and pictures were taken using a ChemiDoc XRS (Biorad).
Mass Spectrometry Analysis. For mass spectrometry analysis,
the protein content of the recovered 50 nm silica corona−
nanoparticles complexes prepared as described above was quantiﬁed
after four centrifugation and washing steps using a Pierce BCA protein
assay kit (ThermoFisher) following the manufacturer’s instructions.
Then, corona−nanoparticle complexes were diluted in PBS in order
to have the same protein concentration for all samples. Samples were
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incubated with the same volume of 0.1% Rapigest (Waters
Chromatography B.V.), an MS-compatible surfactant used to enhance
enzymatic digestion of proteins. Afterward, samples were incubated
for 3 h at 37 °C with 40 μL of a solution of 400 ng of sequencing
grade modiﬁed trypsin (Promega Corporation) resuspended in 0.1%
Rapigest, to allow protein digestion. Samples were shaken every hour
during digestion. The digestion reaction was stopped by adding 10 μL
of 75% v/v acetonitrile and 25% of a solution of 5% v/v formic acid in
water. The nanoparticles and digested peptides were loaded in SPE
(solid phase extraction) GracePure columns (W. R. Grace & Co.).
Columns were ﬁrst equilibrated by adding twice 1 mL of 0.1% v/v
formic acid in acetonitrile and then twice 1 mL of 0.1% v/v formic
acid in water. Then 900 μL of 0.1% v/v formic acid in water was
added to the samples, which were subsequently loaded in the
columns. Samples were washed twice with 1 mL of 0.1% v/v formic
acid in water and then eluted by adding twice 400 μL of 50% v/v
acetonitrile + 0.1% v/v formic acid. The eluted sample was spun down
for 5 min at 16 100 rcf in order to pellet down the remaining
nanoparticles. The supernatant containing the peptides was collected
and dried using a speed vacuum for about 2 h. Afterward, samples
were resuspended in 75 μL of 0.1% formic acid in water, and 2 μL
samples were loaded into a Q Exactive Plus hybrid quadrupole−
orbitrap mass spectrometer (ThermoFisher) using Acclaim PepMap
100 C18 LC columns (ThermoFisher). Samples were analyzed using
the software PEAKS Studio 8.5 (Bioinformatics Solutions Inc.), and
proteins identiﬁed using the manually reviewed UniProtKB/Swiss-
Prot database. Only proteins identiﬁed by at least one unique peptide
were included in the analysis. Spectral counts were normalized by the
molecular weight of the identiﬁed protein and the total normalized
spectral counts used to calculate the relative abundance of each
protein in the corona (% of total).
Uptake Studies with Pharmacological Inhibitors of Trans-
port. HeLa, A549, and HUVEC cells were treated with pharmaco-
logical inhibitors in order to characterize the uptake mechanism of the
corona−nanoparticle complexes formed in low and high serum
content. The optimization of the incubation conditions of the
inhibitors in HeLa cells has been described elsewhere.49 Brieﬂy,
50 000 cells/well were seeded in a 24-well plate (Greiner) 1 day
before the experiments. For HUVEC, wells were precoated with 0.1
mg/mL cold rat-tail collagen type-I (Corning) for 1 h and washed
three times with PBS before cell seeding. Cells were pretreated with
the inhibitors for 10 min (or 20 min for nocodazole) in MEM or
cMEM. The concentrations of inhibitors used in the present work are
the following: 100 μM (HeLa), 40 μM (A549), or 50 μM (HUVEC)
EIPA, 10 μg/mL (HeLa) or 5 μg/mL (A549, HUVEC)
chlorpromazine hydrochloride, 2.5 mg/mL (HeLa), 2 mg/mL
(A549), or 4 mg/mL (HUVEC) methyl-β-cyclodextrin, 25 μg/mL
(HeLa), 50 μg/mL (A549), or 50 μg/mL (HUVEC) dynasore (all
from Sigma-Aldrich), 5 μM (HeLa, A549) or 2.5 μM (HUVEC)
nocodazole (Biovision), 2.5 μg/mL (HeLa, A549) or 0.5 μg/mL
(HUVEC) cytochalasin D (ThermoFisher Scientiﬁc). Afterward, the
corona−nanoparticles complexes were incubated on cells with or
without the inhibitors. Drug eﬃcacy was assessed in parallel for each
experiment by measuring the uptake of markers of endocytosis, by
light microscopy or by immunohistochemistry. As a control for
chlorpromazine and dynasore, the uptake of 2 μg/mL ﬂuorescently
labeled low-density lipoprotein, Dil-LDL (ThermoFisher Scientiﬁc),
dispersed in serum-free MEM was measured. As a control for methyl-
β-cyclodextrin, the uptake of 1 μg/mL BODIPY LacCer (Thermo-
Fisher Scientiﬁc) in serum-free MEM was measured. As a control for
EIPA, the uptake of 250 μg/mL 10 kDa TRITC dextran
(ThermoFisher Scientiﬁc) in cMEM was used.
Flow Cytometry Analysis. HeLa, A549, and HUVEC cells were
incubated with red ﬂuorescently labeled 50 nm silica nanoparticles,
red ﬂuorescently labeled 200 nm silica nanoparticles, Dil-labeled
DOPG−cholesterol liposomes, BODIPY FL C5-LacCer, 10 kDa
TRITC dextran, or Dil-LDL, and their uptake was measured by ﬂow
cytometry. After exposure, cells were washed with cMEM and twice
with PBS to remove the excess nanoparticles and markers and
minimize the eventual contribution of nanoparticles adhering outside
cells.46 Afterward, cells were harvested using 0.05% trypsin−EDTA
for 5 min, centrifuged, resuspended in PBS, and measured
immediately using a Cytoﬂex ﬂow cytometer (Beckman Coulter)
with a 488 or 561 nm laser. Data were analyzed using Flowjo software
(Flowjo, LLC). Dead cells and cell doublets were excluded from the
analysis by setting gates in the forward and side scattering double
scatter plots. At least 20 000 cells were acquired for each sample, and
each condition was repeated in triplicate. Results are expressed as the
average of the median cell ﬂuorescence intensity and standard
deviation over the three technical replicates, unless otherwise stated.
Immunohistochemistry and Fluorescence Imaging. The
eﬃcacy of cytochalasin D and nocodazole on, respectively, actin or
microtubule disruption and the uptake and distribution of 50 nm
silica nanoparticles in HeLa cells was assessed by immunohistochem-
istry. A total of 50 000 cells/well HeLa cells were seeded in a 24-well
plate in which glass coverslips were inserted. After 24 h, the corona
complexes formed on 300 μg/mL 50 nm silica nanoparticles in MEM
supplemented with 12 or 62 mg/mL human serum were isolated as
described above and incubated at a concentration of 100 μg/mL in
serum-free medium for 5 h. Then, cells were washed for 30 min in
MEM supplemented with 10% FBS, in order to remove the excess of
nanoparticles in the incubation medium and on the cell surface. Next,
cells were washed with PBS and ﬁxed by incubation in 4%
formaldehyde for 15 min at room temperature, and the cell membrane
was permeabilized by incubation in 0.1% saponin for 5 min. Then,
HeLa cells treated with nocodazole were incubated for 1 h with a
mouse primary antibody against human α-tubulin (Merck Millipore)
followed by 1 h of incubation with a goat anti-mouse Alexa Fluor488
secondary antibody (ThermoFisher Scientiﬁc). Cells treated with
cytochalasin D were incubated with TRITC-Phalloidin (Sigma-
Aldrich), which selectively stains F-actin. Lysosomal staining was
performed by incubating cells with a mouse primary antibody against
LAMP-1 (clone H4A3, BD Biosciences) for 1 h, followed by 1 h of
incubation with an Alexa Fluor 488 goat secondary anti-mouse
antibody. Cells were washed three times with PBS after each antibody
incubation and subsequently incubated for 5 min with a PBS solution
containing 0.2 μg/mL 4′,6-diamidino-2-phenylindole (DAPI) for
nuclear staining. Finally, the coverslips were mounted on glass slides
using Mowiol 4-88 mounting medium (EMD Chemical, Inc.). Images
were acquired using a Leica TCS SP8 confocal ﬂuorescence
microscope (Leica Microsystems) with a 63× objective, using a 405
nm laser for DAPI excitation, a 488 nm laser for Alexa Fluor488
secondary antibody, and a 552 nm laser for TRITC-Phalloidin.
ImageJ software (http://www.ﬁji.sc) was used for image processing.
Silencing and Competition Experiments. In order to silence
the expression of the LDL receptor in HeLa and A549 cells,
oligofectamine (ThermoFisher) and Silencer Select siRNA (Thermo-
Fisher) were used. Brieﬂy, 13 000 cells/well were seeded in a 24-well
plate (Greiner). Twenty-four hours after seeding, cells were washed in
serum-free MEM for 20 min. Then, each well was incubated with 250
μL of a mix including 1 μL of oligofectamine, 10 pmol of siRNA, and
Opti-MEM (ThermoFisher), prepared according to the manufac-
turer’s instructions. A scrambled siRNA was used as a negative control
(Neg siRNA). After 4 h, 125 μL of MEM supplemented with 30% v/v
fetal bovine serum was added to each well, and cells were grown for a
further 72 h at 37 °C, 5% CO2. After a 72 h silencing, cells were
exposed to the corona complexes or Dil-LDL as described above.
For competition experiments with HUVEC, 50 000 cells/well were
seeded in a 24-well plate (Greiner) precoated with collagen as
described above. Twenty-four hours after seeding, cells were exposed
for 14 h to the corona complexes in serum-free MEM or medium
containing increasing concentrations of unlabeled LDL (BioVision).
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